Application of a small molecule inhibitor screen approach to identify CXCR4 downstream signaling pathways that promote a mesenchymal and fulvestrant-resistant phenotype in breast cancer cells

Bone Marrow Mesenchymal Stem Cell (BMSC) Restrains the Angiogenesis in Melanoma Through Stromal-Derived-Factor-1/C-X-C Chemokine Receptor Type 4 (SDF-1/CXCR4)

This study analyzes the effect of BMSC on restraining the angiogenesis in melanoma through inducing SDF-1/CXCR4 channel. 50 female naked rates were equally assigned into NC group, model group, BMSC group, agonist group and positive NC group randomly followed by analysis of pathological changes, and the level of HIF-1, VEG, MVD, SDF-1 and CXCR4. Agonist group showed the highest level of HIF-1α and VEGF and MVD followed by, model group BMSC group, positive NC group and NC group with no different between BMSC group and positive NC group. SDF-1 and CXCR4 expression was highest in agonist group, followed by that in model group, positive NC group, BMSC group and NC group without difference between model group and positive NC group. In conclusion, SDF-1/CXCR4 activity could be restrained by BMSC partly along with reduced level of HIF-1α and VEGF. This is mainly related with restraining the SDF-1/CXCR4 channel, indicating that it could be adopted as a brand-new therapeutic target for treating melanoma.